NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple-Drug cocktail targets tough lung cancer
Disease control OngoingThis phase 2 study tests whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab can shrink tumors in people with advanced non-squamous lung cancer that has worsened after prior treatment. The trial enrolls 29 adults whose tumors have certain geneti…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 24, 2026 04:19 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control OngoingThis Phase 3 trial tests whether adding the experimental drug AK112 (ivonescimab) to standard chemotherapy can help people with advanced EGFR-mutant non-squamous lung cancer whose targeted therapy has failed. About 322 participants will receive either AK112 or a placebo, plus pem…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 24, 2026 04:17 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New hope for lung cancer patients whose first treatment stopped working
Disease control OngoingThis study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer with an EGFR mutation) whose cancer has worsened after initial targeted therapy. About 420 pa…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC